Thomas Spector

4.4k total citations · 1 hit paper
61 papers, 3.9k citations indexed

About

Thomas Spector is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Thomas Spector has authored 61 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 17 papers in Oncology and 9 papers in Infectious Diseases. Recurrent topics in Thomas Spector's work include Biochemical and Molecular Research (17 papers), Colorectal Cancer Treatments and Studies (10 papers) and HIV/AIDS drug development and treatment (9 papers). Thomas Spector is often cited by papers focused on Biochemical and Molecular Research (17 papers), Colorectal Cancer Treatments and Studies (10 papers) and HIV/AIDS drug development and treatment (9 papers). Thomas Spector collaborates with scholars based in United States, Russia and Canada. Thomas Spector's co-authors include Vincent Massey, Robert E. Parks, Ram P. Agarwal, Joan A. Harrington, Thomas A. Krenitsky, David Porter, Willard W. Hall, Larry G. Howell, C. G. Lis and Robert D. Levin and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Biochemistry.

In The Last Decade

Thomas Spector

61 papers receiving 3.6k citations

Hit Papers

Refinement of the Coomassie blue method of protein quanti... 1978 2026 1994 2010 1978 400 800 1.2k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Spector United States 28 1.9k 552 485 315 309 61 3.9k
Edgar Pick Israel 40 2.9k 1.5× 333 0.6× 382 0.8× 239 0.8× 271 0.9× 126 7.9k
Donald Armstrong United States 39 1.7k 0.9× 375 0.7× 587 1.2× 376 1.2× 105 0.3× 151 5.2k
Hiroshi Nakajima Japan 44 2.8k 1.5× 394 0.7× 486 1.0× 323 1.0× 107 0.3× 370 6.7k
Donald L. Hill United States 38 3.0k 1.6× 821 1.5× 347 0.7× 211 0.7× 192 0.6× 167 4.8k
Vincenzo Zappia Italy 41 2.6k 1.4× 441 0.8× 355 0.7× 99 0.3× 289 0.9× 124 5.3k
Thomas L. Leto United States 57 4.7k 2.5× 394 0.7× 580 1.2× 384 1.2× 437 1.4× 124 11.0k
Antonio Macho Spain 29 4.1k 2.2× 572 1.0× 501 1.0× 160 0.5× 122 0.4× 68 6.4k
Nicholas M. Kredich United States 40 3.0k 1.6× 315 0.6× 360 0.7× 160 0.5× 341 1.1× 75 4.5k
Vera Bianchi Italy 39 2.6k 1.3× 457 0.8× 415 0.9× 406 1.3× 422 1.4× 129 4.4k
Abraham Novogrodsky Israel 40 3.0k 1.6× 614 1.1× 254 0.5× 107 0.3× 144 0.5× 155 5.9k

Countries citing papers authored by Thomas Spector

Since Specialization
Citations

This map shows the geographic impact of Thomas Spector's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Spector with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Spector more than expected).

Fields of papers citing papers by Thomas Spector

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Spector. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Spector. The network helps show where Thomas Spector may publish in the future.

Co-authorship network of co-authors of Thomas Spector

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Spector. A scholar is included among the top collaborators of Thomas Spector based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Spector. Thomas Spector is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rivera, Edgardo, Jenny C. Chang, Semiglazov Vf, et al.. (2013). Eniluracil Plus 5-Fluorouracil and Leucovorin: Treatment for Metastatic Breast Cancer Patients in Whom Capecitabine Treatment Rapidly Failed. Clinical Breast Cancer. 14(1). 26–30. 7 indexed citations
2.
Levin, Robert D., et al.. (2013). Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 72(1). 139–146. 176 indexed citations
3.
Spector, Thomas & Shousong Cao. (2010). A Possible Cause and Remedy for the Clinical Failure of 5-Fluorouracil Plus Eniluracil. Clinical Colorectal Cancer. 9(1). 52–54. 9 indexed citations
4.
Paff, Melanie, David P. Baccanari, Stephen T. Davis, et al.. (2000). Preclinical Development of Eniluracil: Enhancing the Therapeutic Index and Dosing Convenience of 5-Fluorouracil. Investigational New Drugs. 18(4). 365–371. 9 indexed citations
5.
Porter, David, et al.. (1995). Enzymatic elimination of fluoride from α-fluoro-β-alanine. Biochemical Pharmacology. 50(9). 1475–1484. 14 indexed citations
6.
Porter, David, et al.. (1994). 5-Ethynyl-2(1H)-pyrimidinone: Aldehyde oxidase-activation to 5-ethynyluracil, a mechanism-based inactivator of dihydropyrimidine dehydrogenase. Biochemical Pharmacology. 47(7). 1165–1171. 14 indexed citations
7.
Cao, Shousong, Youcef M. Rustum, & Thomas Spector. (1994). 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.. PubMed. 54(6). 1507–10. 95 indexed citations
8.
Porter, David, et al.. (1994). (R)-5-Fluoro-5,6-dihydrouracil: Kinetics of oxidation by dihydropyrimidine dehydrogenase and hydrolysis by dihydropyrimidine aminohydrolase. Biochemical Pharmacology. 48(4). 775–779. 13 indexed citations
9.
Spector, Thomas, Joan A. Harrington, & David Porter. (1993). 5-ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochemical Pharmacology. 46(12). 2243–2248. 88 indexed citations
10.
Furfine, Eric S., et al.. (1992). Two-step binding mechanism for HIV protease inhibitors. Biochemistry. 31(34). 7886–7891. 54 indexed citations
11.
Spector, Thomas, Joan A. Harrington, & David Porter. (1991). Herpes and human ribonucleotide reductases. Biochemical Pharmacology. 42(1). 91–96. 26 indexed citations
12.
Harrington, Joan A. & Thomas Spector. (1991). Human ribonucleotide reductase. Biochemical Pharmacology. 42(4). 759–763. 6 indexed citations
13.
Spector, Thomas, Willard W. Hall, David Porter, et al.. (1989). Inhibition of xanthine oxidase by 4-hydroxy-6-mercaptopyrazolo[3,4-d]pyrimidine. Biochemical Pharmacology. 38(23). 4315–4320. 10 indexed citations
14.
Spector, Thomas, et al.. (1989). Glucuronidation of 3'-azido-3'-deoxythymidine: Human and rat enzyme specificity. Biochemical Pharmacology. 38(9). 1389–1393. 45 indexed citations
15.
Spector, Thomas & Joan A. Harrington. (1989). Rapid sampling of multiple enzyme reactions. Journal of Virological Methods. 26(2). 237–243. 3 indexed citations
16.
Spector, Thomas, Jacqueline Stonehuerner, Karen K. Biron, & D R Averett. (1987). Ribonucleotide reductase induced by varicella zoster virus. Biochemical Pharmacology. 36(24). 4341–4346. 24 indexed citations
17.
Spector, Thomas. (1985). Improvement of a Simple Method to Purify Ribonucleotide Reductase. Preparative Biochemistry. 15(3). 183–188. 10 indexed citations
18.
Spector, Thomas, Randolph L. Berens, & J. Joseph Marr. (1982). Adenylosuccinate synthetase and adenylosuccinate lyase from trypanosoma cruzi. Biochemical Pharmacology. 31(2). 225–229. 38 indexed citations
19.
Spector, Thomas. (1978). Refinement of the Coomassie blue method of protein quantitation. Analytical Biochemistry. 86(1). 142–146. 1496 indexed citations breakdown →
20.
Spector, Thomas & Vincent Massey. (1972). p-Hydroxybenzoate Hydroxylase from Pseudomonas fluorescens. Journal of Biological Chemistry. 247(17). 5632–5636. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026